NR3C1 and non-small cell lung carcinoma: 60 of these potential anticancer drugs are glucocorticoid steroids targeting the glucocorticoid receptor NR3C1, which is a first neighbour of the cancer-related protein PPARG in breast cancer and NSCLC.